CTCAE Adverse Event Grading in Tigilanol Tiglate Trials: How EBC-46 Clinical Safety Is Measured
CTCAE v5.0 framework explained — how Common Terminology Criteria for Adverse Events grade severity in tigilanol tiglate (EBC-46) clinical trials.
Adverse event reporting is one of the most consequential parts of any clinical trial. It is also one of the most easily misread by readers who only see headline figures. In tigilanol tiglate (EBC-46) trials, as in essentially every modern oncology trial, adverse events are graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Understanding what those grades mean is essential to reading the safety data accurately.
What CTCAE actually does
CTCAE provides a standardised dictionary of adverse events and a five-level severity grading scheme. Each event term — "injection-site pain," "fatigue," "hypotension," hundreds more — has explicit grade definitions. Grade 1 is generally mild, asymptomatic or mild symptoms not requiring intervention. Grade 2 is moderate, requiring minimal intervention and limiting age-appropriate instrumental activities of daily living. Grade 3 is severe or medically significant but not immediately life-threatening. Grade 4 indicates life-threatening consequences requiring urgent intervention. Grade 5 is death related to the adverse event.
The point of this scheme is comparability. A Grade 2 fatigue in a tigilanol tiglate trial is defined the same way as a Grade 2 fatigue in a chemotherapy trial — at least in principle. That allows regulators and reviewers to compare safety profiles across compounds and across trials.
What the published tigilanol tiglate data show
Published Phase I and II data on intratumoural tigilanol tiglate, summarised in trial registry entries on ClinicalTrials.gov, show a profile dominated by local rather than systemic events. The most frequently reported adverse events in human studies are injection-site pain, swelling, and a wound that develops at the treated lesion as the tumour collapses. These map predominantly to Grade 1 and Grade 2 events under CTCAE definitions, with Grade 3 events reported in a minority of patients and almost always associated with the treated site rather than systemic toxicity.
Systemic adverse events — fatigue, pyrexia, transient laboratory abnormalities — are typically reported at lower frequencies and at lower grades. The dominant safety signal, in plain English, is "the injection site behaves like an acute wound for several weeks." That signal is consistent with the mechanism of action: rapid tumour collapse leaves a wound that needs to heal.
Why grade distribution matters more than counts
A common misreading of trial safety tables is to focus on the total number of patients reporting a given event. The grade distribution matters far more. A 60% incidence of Grade 1 injection-site pain looks very different from a 60% incidence of Grade 3 injection-site pain — the underlying biology may be similar, but the clinical management requirements are very different. Reviewers therefore look at maximum-grade-per-patient summaries alongside any-grade incidence.
This is also why dose-finding trials report the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) using grade thresholds. A Grade 3 injection-site reaction at a particular dose may trigger a DLT designation, while the same any-grade injection-site reaction at a lower dose may not.
Reading attribution
CTCAE grading is paired with attribution — the investigator's judgement of whether an event was unrelated, unlikely, possible, probable, or definitely related to the study agent. For an intratumoural injection, attribution for local events is generally straightforward. Systemic events require more careful adjudication and are why trial protocols mandate that an independent safety monitoring committee reviews the data periodically.
How this connects to the rest of the EBC-46 trial picture
Reading the CTCAE tables alongside other parts of the trial is what produces a useful picture. The pharmacokinetic profile of tigilanol tiglate — short half-life, low systemic exposure after intratumoural dosing — helps explain why systemic adverse events are uncommon. The article on injection-site response and wound healing describes the clinical management of the dominant local adverse event. The veterinary FDA approval of Stelfonta (tigilanol tiglate injection) for canine mast cell tumours provides additional safety data in a related context.
What CTCAE grading does not tell you
CTCAE grades severity but not patient experience or quality of life. Two trials reporting identical CTCAE distributions can produce very different patient-reported outcomes. That is why modern oncology trials pair CTCAE with patient-reported outcome measures and quality-of-life instruments — and it's why those endpoints are increasingly published alongside the safety tables.
It is also worth restating scope: the discussion above relates to investigational pharmaceutical-grade injectable tigilanol tiglate. Oral blushwood berry extract dietary supplements are a separate product category. Reference suppliers in the supplement space — see blushwood.health for an example — make no therapeutic claims and frame their products within the established dietary supplement framework.
References
1. NCI — Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
2. U.S. National Library of Medicine — ClinicalTrials.gov: Tigilanol Tiglate Trials.
